Pharmaceutical

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer

The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.

Jul 20, 2024 - 04:00
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.
Read the original article

Tags:

Previous Article

Global study by Hawaiʻi Institute of Marine Biology demonstrates benefit of mari...

Next Article

Tech leader’s $125m boosts Parker Institutes immunotherapy research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA warns of reduced efficacy for oral birth control pill Tydemy

FDA warns of reduced efficacy for oral birth control pi...

Aug 2, 2023

An Ask Me Anything with STAT’s Nicholas St. Fleur

An Ask Me Anything with STAT’s Nicholas St. Fleur

Oct 28, 2023

ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer

ImmunoPrecise and Biotheus partner on bispecific antibo...

Oct 4, 2024